Polycystic Ovarian Syndrome (PCOS) Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Drug Class (Antiandrogens, Insulin Sensitizers, Oral Contraceptives, Weight Loss Medications); By Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Size Set to Touch USD 5.5 Billion by 2029
Global polycystic ovarian syndrome (PCOS) treatment market is flourishing because of the growing prevalence of PCOS and increasing awareness about PCOS.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global polycystic ovarian syndrome (PCOS) treatment market size at USD 4.02 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global polycystic ovarian syndrome (PCOS) treatment market size to grow at a significant CAGR of 5.24% reaching a value of USD 5.46 billion by 2029. Major growth drivers for the global polycystic ovarian syndrome (PCOS) treatment market include an increasing awareness of the condition and a rising number of diagnosed cases. The market growth is influenced by the prevalence of PCOS, changing lifestyles, and healthcare infrastructure developments. Notably, heightened awareness among the patient population about PCOS and its management, along with the adoption of combination therapy, are key factors contributing to the market's expansion. Also, the market's overall growth is expected to be further accelerated by factors such as the rising incidence of diabetes and obesity among women, an increase in hormonal disorders affecting women, socioeconomic considerations, shifts towards sedentary lifestyles, and increased consumption of unhealthy dietary options. Hence, such aspects are expected to boost the expansion of global polycystic ovarian syndrome (PCOS) treatment market during the forecast period. However, side effects of PCOS medications and high cost of PCOS treatment are anticipated to restrain the overall market growth during the period in analysis.
Global Polycystic Ovarian Syndrome (PCOS) Treatment Market – Overview
The global polycystic ovarian syndrome (PCOS) treatment market refers to the collective industry and market activities related to the development, manufacturing, distribution, and commercialization of medical products, pharmaceuticals, therapies, and services aimed at diagnosing, managing, and treating polycystic ovarian syndrome (PCOS). PCOS is a common hormonal disorder affecting individuals, primarily women, of reproductive age. This market encompasses a wide range of interventions, including pharmaceutical drugs, lifestyle management programs, medical devices, and healthcare services, all designed to alleviate the symptoms and complications associated with PCOS, such as irregular menstrual periods, hormonal imbalances, and related health issues. The market's growth is influenced by factors such as the prevalence of PCOS, evolving treatment approaches, research and development efforts, and changes in healthcare policies and patient awareness.
Impact of COVID-19 on Global Polycystic Ovarian Syndrome (PCOS) Treatment Market
COVID-19 pandemic adversely affected the global polycystic ovarian syndrome (PCOS) treatment market. Pandemic-related disruptions in healthcare access, reduced medical visits, and delayed diagnoses led to a decline in new PCOS cases being identified and treated. Patients' reluctance to seek in-person medical care further slowed market growth. Additionally, supply chain disruptions affected the availability of PCOS medications and treatments, leading to fluctuations in product availability and pricing. However, the pandemic also accelerated the adoption of telemedicine for PCOS management, offering a potential avenue for future market growth. Overall, the COVID-19 pandemic created a complex and dynamic environment for PCOS treatment, affecting both demand and supply aspects.
Global Polycystic Ovarian Syndrome (PCOS) Treatment Market – By Distribution Channel
Based on distribution channel, the global polycystic ovarian syndrome (PCOS) treatment market is divided into Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers segments. The hospital pharmacy segment held the highest share in the global PCOS treatment market by distribution channel. It can be attributed to the growing demand for oral contraceptives and various treatments related to polycystic ovarian syndrome (PCOS). The significant market share held by hospital pharmacies can also be ascribed to the extensive availability of treatment options and medications addressing costly aspects of PCOS care. These encompass treatments for enduring metabolic health conditions like type-2 diabetes and addressing reproductive health concerns such as infertility, abnormal uterine bleeding, menstrual dysfunction, and hirsutism. Consequently, hospital pharmacies stand out as the preferred choice for PCOS patients seeking comprehensive and specialized care.
Competitive Landscape
Major players operating in the global polycystic ovarian syndrome (PCOS) treatment market include Mylan N.V, Johnson and Johnson, Teva Pharmaceutical Industries, Novartis AG, SANOFI, Allergan plc, Bristol-Myers Squibb Company, Bayer AG, AstraZeneca plc, and Pfizer Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Polycystic Ovarian Syndrome (PCOS) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Polycystic Ovarian Syndrome (PCOS) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
- 1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
- 2. Executive Summary
- 3. Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Rising prevalence of PCOS
- 3.2.1.2. Increasing awareness of PCOS
- 3.2.2. Restraints
- 3.2.2.1. Side effects of PCOS medications
- 3.2.2.2. High cost of PCOS treatment
- 3.2.3. Opportunities
- 3.2.3.1. Development of new PCOS treatments
- 3.2.3.2. Expanding access to PCOS treatment
- 3.2.4. Challenges
- 3.2.4.1. Stigma associated with PCOS
- 3.2.4.2. Disparities in PCOS care
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter’s Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
- 4. Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
- 4.1. Market Drug Class & Forecast, 2019–2029
- 4.1.1. By Value (USD Billion)
- 4.2. Market Share and Forecast
- 4.2.1. By Drug Class
- 4.2.1.1. Antiandrogens
- 4.2.1.2. Insulin Sensitizers
- 4.2.1.3. Oral Contraceptives
- 4.2.1.4. Weight Loss Medications
- 4.2.1.5. Others
- 4.2.2. By Distribution Channel
- 4.2.2.1. Hospital Pharmacy
- 4.2.2.2. Drug Store & Retail Pharmacy
- 4.2.2.3. Online Providers
- 4.2.3. By Region
- 4.2.3.1. North America
- 4.2.3.2. Europe
- 4.2.3.3. Asia Pacific (APAC)
- 4.2.3.4. Latin America (LATAM)
- 4.2.3.5. Middle East and Africa (MEA)
- 5. North America Polycystic Ovarian Syndrome (PCOS) Treatment Market
- 5.1. Market Drug Class & Forecast, 2019–2029
- 5.1.1. By Value (USD Billion)
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Class
- 5.2.2. By Distribution Channel
- 5.2.3. By Country
- 5.2.3.1. United States
- 5.2.3.1.1. By Drug Class
- 5.2.3.1.2. By Distribution Channel
- 5.2.3.2. Canada
- 5.2.3.2.1. By Drug Class
- 5.2.3.2.2. By Distribution Channel
- 6. Europe Polycystic Ovarian Syndrome (PCOS) Treatment Market
- 6.1. Market Drug Class & Forecast, 2019–2029
- 6.1.1. By Value (USD Billion)
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Distribution Channel
- 6.2.3. By Country
- 6.2.3.1. Germany
- 6.2.3.1.1. By Drug Class
- 6.2.3.1.2. By Distribution Channel
- 6.2.3.2. United Kingdom
- 6.2.3.2.1. By Drug Class
- 6.2.3.2.2. By Distribution Channel
- 6.2.3.3. Italy
- 6.2.3.3.1. By Drug Class
- 6.2.3.3.2. By Distribution Channel
- 6.2.3.4. France
- 6.2.3.4.1. By Drug Class
- 6.2.3.4.2. By Distribution Channel
- 6.2.3.5. Spain
- 6.2.3.5.1. By Drug Class
- 6.2.3.5.2. By Distribution Channel
- 6.2.3.6. Belgium
- 6.2.3.6.1. By Drug Class
- 6.2.3.6.2. By Distribution Channel
- 6.2.3.7. Russia
- 6.2.3.7.1. By Drug Class
- 6.2.3.7.2. By Distribution Channel
- 6.2.3.8. The Netherlands
- 6.2.3.8.1. By Drug Class
- 6.2.3.8.2. By Distribution Channel
- 6.2.3.9. Rest of Europe
- 6.2.3.9.1. By Drug Class
- 6.2.3.9.2. By Distribution Channel
- 7. Asia-Pacific Polycystic Ovarian Syndrome (PCOS) Treatment Market
- 7.1. Market Drug Class & Forecast, 2019–2029
- 7.1.1. By Value (USD Billion)
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Country
- 7.2.3.1. China
- 7.2.3.1.1. By Drug Class
- 7.2.3.1.2. By Distribution Channel
- 7.2.3.2. India
- 7.2.3.2.1. By Drug Class
- 7.2.3.2.2. By Distribution Channel
- 7.2.3.3. Japan
- 7.2.3.3.1. By Drug Class
- 7.2.3.3.2. By Distribution Channel
- 7.2.3.4. South Korea
- 7.2.3.4.1. By Drug Class
- 7.2.3.4.2. By Distribution Channel
- 7.2.3.5. Australia & New Zealand
- 7.2.3.5.1. By Drug Class
- 7.2.3.5.2. By Distribution Channel
- 7.2.3.6. Indonesia
- 7.2.3.6.1. By Drug Class
- 7.2.3.6.2. By Distribution Channel
- 7.2.3.7. Malaysia
- 7.2.3.7.1. By Drug Class
- 7.2.3.7.2. By Distribution Channel
- 7.2.3.8. Singapore
- 7.2.3.8.1. By Drug Class
- 7.2.3.8.2. By Distribution Channel
- 7.2.3.9. Vietnam
- 7.2.3.9.1. By Drug Class
- 7.2.3.9.2. By Distribution Channel
- 7.2.3.10. Rest of APAC
- 7.2.3.10.1. By Drug Class
- 7.2.3.10.2. By Distribution Channel
- 8. Latin America Polycystic Ovarian Syndrome (PCOS) Treatment Market
- 8.1. Market Drug Class & Forecast, 2019–2029
- 8.1.1. By Value (USD Billion)
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Distribution Channel
- 8.2.3. By Country
- 8.2.3.1. Brazil
- 8.2.3.1.1. By Drug Class
- 8.2.3.1.2. By Distribution Channel
- 8.2.3.2. Mexico
- 8.2.3.2.1. By Drug Class
- 8.2.3.2.2. By Distribution Channel
- 8.2.3.3. Argentina
- 8.2.3.3.1. By Drug Class
- 8.2.3.3.2. By Distribution Channel
- 8.2.3.4. Peru
- 8.2.3.4.1. By Drug Class
- 8.2.3.4.2. By Distribution Channel
- 8.2.3.5. Rest of LATAM
- 8.2.3.5.1. By Drug Class
- 8.2.3.5.2. By Distribution Channel
- 9. Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Treatment Market
- 9.1. Market Drug Class & Forecast, 2019–2029
- 9.1.1. By Value (USD Billion)
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Country
- 9.2.3.1. Saudi Arabia
- 9.2.3.1.1. By Drug Class
- 9.2.3.1.2. By Distribution Channel
- 9.2.3.2. UAE
- 9.2.3.2.1. By Drug Class
- 9.2.3.2.2. By Distribution Channel
- 9.2.3.3. Qatar
- 9.2.3.3.1. By Drug Class
- 9.2.3.3.2. By Distribution Channel
- 9.2.3.4. Kuwait
- 9.2.3.4.1. By Drug Class
- 9.2.3.4.2. By Distribution Channel
- 9.2.3.5. South Africa
- 9.2.3.5.1. By Drug Class
- 9.2.3.5.2. By Distribution Channel
- 9.2.3.6. Nigeria
- 9.2.3.6.1. By Drug Class
- 9.2.3.6.2. By Distribution Channel
- 9.2.3.7. Algeria
- 9.2.3.7.1. By Drug Class
- 9.2.3.7.2. By Distribution Channel
- 9.2.3.8. Rest of MEA
- 9.2.3.8.1. By Drug Class
- 9.2.3.8.2. By Distribution Channel
- 10. Competitive Landscape
- 10.1. List of Key Players and Their Offerings
- 10.2. Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Share Analysis, 2022
- 10.3. Competitive Benchmarking, By Operating Parameters
- 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
- 11. Impact of Covid-19 on Global Polycystic Ovarian Syndrome (PCOS) Treatment Market
- 12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
- 12.1. Mylan N.V
- 12.2. Johnson and Johnson
- 12.3. Teva Pharmaceutical Industries
- 12.4. Novartis AG
- 12.5. SANOFI
- 12.6. Allergan plc
- 12.7. Bristol-Myers Squibb Company
- 12.8. Bayer AG.
- 12.9. AstraZeneca plc
- 12.10. Pfizer Inc.
- 12.11. Other Prominent Players
- 13. Key Strategic Recommendations
- 14. Research Methodology
- 14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
- 14.2. Quantitative Research
- 14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
- 14.4. Breakdown of Primary Research Respondents, By Region
- 14.5. Assumptions & Limitations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook